Allsopp L F, Huitson A, Deering R B, Brodie N H
J Int Med Res. 1985;13(4):203-8. doi: 10.1177/030006058501300402.
This multicentre double-blind trial in general practice compared the efficacy and tolerability of the sustained-release formulation of clomipramine (Anafranil SR) with its conventional formulation (Anafranil) in the treatment of phobias. Patients were allocated at random to receive clomipramine 75 mg once daily as either the sustained-release or conventional formulation for 11 weeks following a 1-week dosage build-up period. Analysis of results from forty-six patients showed that the sustained release formulation of clomipramine 75 mg was as effective as the conventional formulation of clomipramine 75 mg in improving symptoms of phobia as assessed by a phobia inventory and global evaluation. Unwanted effects attributable to therapy were similar in both treatment groups but there were fewer withdrawals due to unwanted effects of the sustained release formulation of clomipramine 75 mg. It was concluded that the sustained-release formulation of clomipramine does offer advantages for patients requiring 75 mg clomipramine daily.
这项在全科医疗中开展的多中心双盲试验，比较了氯米帕明缓释制剂（Anafranil SR）与其传统制剂（Anafranil）治疗恐惧症的疗效和耐受性。在1周的剂量递增期后，患者被随机分配，每天服用一次75毫克氯米帕明，剂型为缓释制剂或传统制剂，持续11周。对46名患者的结果分析表明，就恐惧症量表和整体评估所评估的情况而言，75毫克氯米帕明缓释制剂在改善恐惧症症状方面与75毫克氯米帕明传统制剂效果相当。两个治疗组中因治疗引起的不良反应相似，但因75毫克氯米帕明缓释制剂不良反应导致的停药情况较少。得出的结论是，对于每日需要75毫克氯米帕明的患者，氯米帕明缓释制剂确实具有优势。
